Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Norman Lamaida"'
Autor:
Vincenzo Capuano, Norman Lamaida, Rocco Capuano, Eduardo Capuano, Sergio Torre, Federica Marchese, Ernesto Capuano
Publikováno v:
Monaldi Archives for Chest Disease, Vol 82, Iss 4 (2015)
Background: Data relating to non-fatal cardiovascular events are poor but these data are essential to organize targeted interventions on the territory and to understand their effectiveness. Methods: We calculated the rates of morbidity from cardiovas
Externí odkaz:
https://doaj.org/article/5b911f9a08f74d6a94bf9037f15fb051
Autor:
Vincenzo Capuano, Norman Lamaida, Sergio Torre, Ernesto Capuano, Maria Immacolata Borrelli, Eduardo Capuano, Maria Maddalena Clarizia, Rocco Capuano, Carmela De Rosa
Publikováno v:
Monaldi Archives for Chest Disease, Vol 80, Iss 1 (2015)
Rationale: In Italy the mortality data were obtained almost exclusively from the data RENCAM (Name Causes of Death Register), while there are few prospective surveys. In order to assess whether there are particular epidemiological conditions in the g
Externí odkaz:
https://doaj.org/article/77eeb4037bd54b16b87eb81305c2d0d1
Autor:
Norman Lamaida, Antonio Cerciello
Publikováno v:
European Heart Journal Supplements. 24
Background :Heart failure (HF) with reduced ejection fraction (HFrEF) remains a challenging problem due to its high mortality rate. Another novelty in HF therapy is dapagliflozin, a sodium–glucose transporter–2 inhibitor (SGLT2i) which decreased
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::857d6222f02fd632b8a6411d9e6ea889
https://doi.org/10.1093/eurheartjsupp/suac121.149
https://doi.org/10.1093/eurheartjsupp/suac121.149
Autor:
Norman Lamaida, Antonio Cerciello
Publikováno v:
European Heart Journal Supplements. 24
Dapaglifozin on diastolic function in patients with type 2 diabetic mellitus and chronic heart failure Heart failure (HF) with reduced ejection fraction (HFrEF) remains a challenging problem due to its high mortality rate. Another novelty in HF thera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::48ed4ddda49d6499d0ffec8ab2be456c
https://doi.org/10.1093/eurheartjsupp/suac121.150
https://doi.org/10.1093/eurheartjsupp/suac121.150
Autor:
Norman Lamaida, Antonio Cerciello
Publikováno v:
European Heart Journal Supplements. 24
Background Carotid Doppler ultrasonography (USG) is widely used to measure haemodynamic parameters, such as Intima–Media Thickness (IMT) and blood flow velocities (i.e. Peak–Systolic Velocity [PSV], End–Diastolic Velocity [EDV], and Resistive I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c3a48fd4a279a85ee7cdf72f5d2e9e63
https://doi.org/10.1093/eurheartjsupp/suac121.403
https://doi.org/10.1093/eurheartjsupp/suac121.403
Autor:
Ernesto Capuano, Norman Lamaida, Raffaella Sica, Marzia Manilia, Vincenzo Capuano, Rocco Capuano, Anna Grazia Iannone, Eduardo Capuano, Federica Marchese
Publikováno v:
World Journal of Cardiovascular Diseases. 11:145-152
Background: Stroke is the second leading cause of death in the world and the third due to disability. However, there are few data available that identify the risk factors associated with it and their weight in different populations (population risk).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e0c71184e4dbf9ed9ed4fa5a03c3385c
https://doi.org/10.4236/wjcd.2021.112016
https://doi.org/10.4236/wjcd.2021.112016
Publikováno v:
European Heart Journal Supplements. 23
Aims The incidence of atrial fibrillation (AF) increases with age. The risk of stroke is increased 4- to 5-fold in old patients with AF. In the Framingham Study, 23.5% of strokes in patients aged 80 and older were attributable to AF. Advanced age is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ac2aad405f359eea4d4c1ca3847fb428
https://doi.org/10.1093/eurheartj/suab131.006
https://doi.org/10.1093/eurheartj/suab131.006
Autor:
Antonio Cerciello, Norman Lamaida
Publikováno v:
European Heart Journal Supplements. 23
Aims The PARADIGM-HF study has shown, as is well known, that the association of sacubitril/valsartan (SV) was superior in terms of efficacy compared to enalapril in patients suffering from heart failure chronic cardiac (SC) and reduced systolic funct
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::320f76b536555ecc952d8a458f3b4b13
https://doi.org/10.1093/eurheartj/suab139.020
https://doi.org/10.1093/eurheartj/suab139.020
Autor:
Norman Lamaida, Antonio Cerciello
Publikováno v:
European Heart Journal Supplements. 23
Aims The PARADIGM-HF trial proved the superiority of sacubitril/valsartan (Sa/Va) vs. enalapril in reducing mortality and hospitalization for heart failure (HF). Sacubitril/valsartan, new drug used in treatment of heart failure with reduced systolic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5eccfc0002b0cfe6ec1e0302e73768b4
https://doi.org/10.1093/eurheartj/suab139.019
https://doi.org/10.1093/eurheartj/suab139.019
Autor:
Ernesto Capuano, Sergio Torre, Federica Marchese, Vincenzo Capuano, Matteo Sonderegger, Rocco Capuano, Eduardo Capuano, Norman Lamaida, Anna Grazia Iannone
Publikováno v:
Journal of Cardiovascular Medicine. 18:159-164
To date, whether hyperuricemia may represent a marker or an independent risk factor for cardiovascular disease remains unclear. This study aimed at assessing the role of hyperuricemia in the onset of major cardiovascular events (MACE).Baseline clinic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b225486c15f2636acc296a026e413571
https://doi.org/10.2459/jcm.0000000000000347
https://doi.org/10.2459/jcm.0000000000000347